Beijing Kawin Technology Share-holding Co Ltd (688687) - Total Assets
Based on the latest financial reports, Beijing Kawin Technology Share-holding Co Ltd (688687) holds total assets worth CN¥2.87 Billion CNY (≈ $419.68 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See shareholders equity of Beijing Kawin Technology Share-holding C for net asset value and shareholders' equity analysis.
Beijing Kawin Technology Share-holding Co Ltd - Total Assets Trend (2008–2024)
This chart illustrates how Beijing Kawin Technology Share-holding Co Ltd's total assets have evolved over time, based on quarterly financial data.
Beijing Kawin Technology Share-holding Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Beijing Kawin Technology Share-holding Co Ltd's total assets of CN¥2.87 Billion consist of 71.1% current assets and 28.9% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 34.5% |
| Accounts Receivable | CN¥430.01 Million | 16.4% |
| Inventory | CN¥144.24 Million | 5.5% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥202.83 Million | 7.8% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2008–2024)
This chart illustrates how Beijing Kawin Technology Share-holding Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Beijing Kawin Technology Share-holding C market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Beijing Kawin Technology Share-holding Co Ltd's current assets represent 71.1% of total assets in 2024, an increase from 30.9% in 2008.
- Cash Position: Cash and equivalents constituted 34.5% of total assets in 2024, up from 30.9% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 7.0% of total assets, an increase from 3.0% in 2008.
- Asset Diversification: The largest asset category is accounts receivable at 16.4% of total assets.
Beijing Kawin Technology Share-holding Co Ltd Competitors by Total Assets
Key competitors of Beijing Kawin Technology Share-holding Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.06 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥819.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.16 Billion |
Beijing Kawin Technology Share-holding Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.75 | 3.11 | 3.17 |
| Quick Ratio | 2.55 | 2.91 | 2.85 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.31 Billion | CN¥1.29 Billion | CN¥542.87 Million |
Beijing Kawin Technology Share-holding Co Ltd - Advanced Valuation Insights
This section examines the relationship between Beijing Kawin Technology Share-holding Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.07 |
| Latest Market Cap to Assets Ratio | 0.19 |
| Asset Growth Rate (YoY) | 6.8% |
| Total Assets | CN¥2.62 Billion |
| Market Capitalization | $494.29 Million USD |
Valuation Analysis
Below Book Valuation: The market values Beijing Kawin Technology Share-holding Co Ltd's assets below their book value (0.19x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Beijing Kawin Technology Share-holding Co Ltd's assets grew by 6.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Beijing Kawin Technology Share-holding Co Ltd (2008–2024)
The table below shows the annual total assets of Beijing Kawin Technology Share-holding Co Ltd from 2008 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.62 Billion ≈ $382.75 Million |
+6.84% |
| 2023-12-31 | CN¥2.45 Billion ≈ $358.25 Million |
+10.79% |
| 2022-12-31 | CN¥2.21 Billion ≈ $323.35 Million |
+1.47% |
| 2021-12-31 | CN¥2.18 Billion ≈ $318.67 Million |
+85.78% |
| 2020-12-31 | CN¥1.17 Billion ≈ $171.53 Million |
+11.37% |
| 2019-12-31 | CN¥1.05 Billion ≈ $154.02 Million |
+29.21% |
| 2018-12-31 | CN¥814.56 Million ≈ $119.20 Million |
+12.57% |
| 2017-12-31 | CN¥723.61 Million ≈ $105.89 Million |
+4.08% |
| 2015-12-31 | CN¥695.21 Million ≈ $101.73 Million |
+58.28% |
| 2014-12-31 | CN¥439.24 Million ≈ $64.27 Million |
+8.82% |
| 2013-12-31 | CN¥403.63 Million ≈ $59.06 Million |
+28.98% |
| 2012-12-31 | CN¥312.94 Million ≈ $45.79 Million |
+48.97% |
| 2011-12-31 | CN¥210.07 Million ≈ $30.74 Million |
+27.46% |
| 2010-12-31 | CN¥164.82 Million ≈ $24.12 Million |
+136.95% |
| 2009-12-31 | CN¥69.56 Million ≈ $10.18 Million |
+117.36% |
| 2008-12-31 | CN¥32.00 Million ≈ $4.68 Million |
-- |
About Beijing Kawin Technology Share-holding Co Ltd
Beijing Kawin Technology Share-Holding Co., Ltd., a biopharmaceutical company, provides treatment solutions for viral and immune diseases in China and internationally. The company offers recombinant human interferon alfa-2b injection; interferon alfa-2b vaginal effervescent tablets; coblopasvir hydrocholoride capsules; sofosbuvir tablets; peginterferon alfacon-2 injection; and compound glycyrrhiz… Read more